Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Inventory (2024 - 2025)

ARS Pharmaceuticals' Inventory history spans 2 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Inventory rose 60.57% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, up 60.57%, while the annual FY2025 figure was $8.4 million, 60.57% up from the prior year.
  • Inventory for Q4 2025 was $8.4 million at ARS Pharmaceuticals, up from $7.8 million in the prior quarter.
  • Across five years, Inventory topped out at $8.7 million in Q2 2025 and bottomed at $715000.0 in Q3 2024.